Quinazoline compounds
AssigneeHutchison Medipharma Limited
InventorsWeihan Zhang, Wei-Guo Su, Haibin Yang, Yumin Cui, Yongxin Ren, Xiaoqiang Yan
Life of this patent
Estimating the term…
Abstract
Provided are certain quinazoline compounds, compositions thereof and methods of use thereof. These quinazoline compounds can effectively inhibit the overexpression and/or overactivity of epidermal growth factor receptor (EGFR).
Claims10
A compound that is (3aR,6aR)—N-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yl)-1-methyl-hexahydropyrrolo[3,4-b]pyrrole-5(1H)-carboxamide;
- or a pharmaceutically acceptable salt thereof.
A method of treating cancer responsive to inhibition of overexpression and/or overactivity of epidermal growth factor receptor, comprising administering to a subject in need thereof an effective amount of (3aR,6aR)—N-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yl)-1-methyl-hexahydropyrrolo[3,4-b]pyrrole-5(1H)-carboxamide;
- or a pharmaceutically acceptable salt thereof, wherein the cancer is selected from the group consisting of lung cancer, non small cell lung cancer, head and neck cancer, pharynx cancer, an epidermoid cancer.
A method of inhibiting over-expression and/or over-activity of epidermal growth factor receptor comprising contacting epidermal growth factor receptor with an effective amount of (3aR,6aR)—N-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yl)-1-methyl-hexahydropyrrolo[3,4-b]pyrrole-5(1H)-carboxamide, or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.